---
symbol: "HIMS"
name: "Hims & Hers"
date: 2026-11-12
change_pct: 6.472306248044226
direction: "up"
event_type: "regulatory_legal"
url: "https://perplo.app/why/HIMS/2026-11-12"
updated_at: 2026-11-12T02:07:27.907Z
---

# Why Hims & Hers (HIMS) rose 6.47% on November 12, 2026

Hims & Hers (HIMS) rose 6.47% on November 12, 2026 — US curb easing opens unapproved peptide sales.

## What happened

Hims & Hers rose 6.5% after saying it will offer unapproved peptides following a US easing of curbs on those products.

## Why it moved

Looser enforcement widens the range of products Hims can sell, which can support near-term revenue growth. For a high-growth telehealth name, a clear new product line is the kind of catalyst that moves the stock quickly.

## Why it matters

Hims is a leading name in the Meme Stocks theme, where stocks trade on sharp narrative shifts and retail momentum.

## What would break the thesis

If regulators reverse course or block the peptide offering, the upside disappears. Also watch whether the product actually launches and whether early sales back up the revenue case.

## Sources

- [Hims & Hers to offer unapproved peptides after US eases curbs](https://www.investing.com/news/stock-market-news/hims--hers-narrows-2026-revenue-forecast-as-margins-contract-5013239) — Investing.com
- [Canaccord reiterates Hims & Hers stock rating after Q3 results](https://www.investing.com/news/analyst-ratings/canaccord-reiterates-hims--hers-stock-rating-after-q3-results-93CH-5014687) — Investing.com

---

Trade HIMS perpetual futures 24/7 onchain: https://perplo.app/asset/HIMS